Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis

Elisabeth Simader; Selma Tobudic; Peter Mandl; Helmuth Haslacher; Thomas Perkmann; Thomas Nothnagl; Judith Sautner; Helga Radner; Florian Winkler; Heinz Burgmann; Daniel Mrak; Daniel Aletaha; Stefan Winkler; Stephan Blüml

doi:10.1136/annrheumdis-2021-221347

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Epidemiology

Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Simader E, Tobudic S, Mandl P, et al

Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis

Annals of the Rheumatic Diseases 2022;81:416-421.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password